Overview
Photodynamic therapy (PDT) uses a photosensitizing drug that accumulates in cancer cells, which is then activated by a specific wavelength of light to produce toxic molecules that kill the cancer cells. It is being studied as an adjunct to surgery for mesothelioma.
Who May Be a Candidate
- Patients undergoing surgical resection
- Clinical trial participants
- Those with localized disease
- Good overall health
How It Works
A photosensitizing agent is given intravenously before surgery. During the operation, after tumor removal, the surgical site is exposed to specific wavelengths of light, activating the drug in any remaining cancer cells.
Procedure Steps
- Photosensitizer drug administered 24-48 hours before surgery
- Standard surgical tumor removal performed
- Light delivered to surgical cavity
- Activated drug produces cell-killing molecules
- Procedure completed and patient recovers
Benefits
- Targets microscopic residual disease after surgery
- Minimal damage to normal tissue
- May reduce local recurrence
- Can be combined with other treatments
Risks & Side Effects
- Skin sensitivity to light (days to weeks)
- Limited depth of light penetration
- Requires specialized equipment
- Available only at specialized centers
Recovery
Similar to standard surgery recovery. Patients must avoid direct sunlight and bright lights for several days to weeks due to skin photosensitivity.
Expected Outcomes
Early studies show PDT may improve local disease control when added to surgery. Larger trials are needed to confirm benefit. Currently available primarily through clinical trials.
Finding Treatment
This procedure is typically performed at specialized mesothelioma treatment centers with experienced surgical teams. Consulting with a mesothelioma specialist is the first step in determining if this treatment is appropriate for your situation.